Fast Facts Acute Myeloid Leukemia

This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acute Myeloid Leukemia' provides a comprehensive yet concise foundation for understanding AML: from basic epidemiology, diagnosis, classification and the current 'standard' treatment, through to recent advances in our understanding of the cytogenetic and molecular underpinnings of the disease, such as the IDH2 mutation, and the future for tailored therapy. It will be useful to primary care providers, medical students, specialist nurses, junior doctors and allied healthcare professionals who want to develop a thorough grounding in our evolving understanding of AML and its treatment. Contents: • Epidemiology, pathophysiology and etiology • Diagnosis • Treatment • Supportive care • Prognosis and monitoring • Emerging treatments • Useful resources

Leukemia is a hematologic malignancy arising from hematopoietic stem cells (HSCs) in the bone marrow. Starting with a detailed description of hematopoiesis and what goes wrong in leukemia, this concise guide covers all aspects of the four most common subtypes of the disease. Although the incidence and prevalence of leukemia are rising worldwide, survival rates are also increasing. However, both the effects of the disease and the adverse effects of treatment remain complex challenges. Yet, as our understanding of the molecular landscape increases, therapeutic options are becoming more personalized. This revised and updated second edition of 'Fast Facts: Leukemia' addresses the causes and risk factors for each subtype of leukemia, the initial and confirmatory diagnostic tests, and the latest treatment options. Designed as a comprehensive primer for physician assistants, nurse practitioners, primary care providers, oncology nurses, hematology/ oncology trainees and pharmacists, this resource will help the non-specialist and those in training to identify leukemia early and provide a thorough understanding of the pathology and genetic basis of the disease, treatment options, and effective approaches to emergency and supportive care. Table of Contents: • Understanding blood and its components • What is leukemia? • Epidemiology, etiology and risk factors • Diagnosis • Staging and general management • Supportive care • Emergencies in leukemia

This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) - following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities - which differ not only between patients but also within a patient over time and with treatment. 'Fast Facts: Acute Myeloid Leukemia' provides a comprehensive yet concise foundation for understanding AML: from basic epidemiology, diagnosis, classification and the current 'standard' treatment, through to recent advances in our understanding of the cytogenetic and molecular underpinnings of the disease, such as the IDH2 mutation, and the future for tailored therapy. It will be useful to primary care providers, medical students, specialist nurses, junior doctors and allied healthcare professionals who want to develop a thorough grounding in our evolving understanding of AML and its treatment. Contents: • Epidemiology, pathophysiology and etiology • Diagnosis • Treatment • Supportive care • Prognosis and monitoring • Emerging treatments • Useful resources.

Acute lymphoblastic leukemia (ALL) is the most diagnosed childhood cancer worldwide. Although rare in adults, this aggressive cancer also shows a second smaller incidence peak in later middle age.

Modern genetic profiling techniques are providing a better understanding of the molecular biology of ALL, which, in turn, is leading to significant advances in diagnosis, prognostication and therapy selection. Ongoing refinement of risk-adapted frontline treatment protocols, use of novel targeted therapies and better supportive care are improving outcomes for patients with ALL.

Fast Facts: Acute Lymphoblastic Leukemia covers the epidemiology, etiology, diagnosis and classification of ALL as well as the measurement of minimal residual disease to determine prognosis. It provides guidance on frontline therapies and the treatment of relapsed and refractory ALL, including the use of newer targeted agents and the role of allogeneic stem-cell transplantation. Looking to the future, it also considers the approaches and refinements that are in development for ALL. Table of Contents:

Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.

Myelodysplastic syndromes (MDS) are a group of clonal myeloid blood disorders that affect older people. As the global population ages, the incidence of these disorders is increasing. As such, healthcare professionals need to be aware of MDS as a possible diagnosis and know how to identify those patients whose condition is most likely to transform to acute myeloid leukemia (AML). Fast Facts: Myelodysplastic Syndromes explains how these disorders are classified, how they present and how prognosis and the risk of transformation to AML are assessed. It also outlines the most appropriate management options for patients of different ages, together with an overview of the latest research under way to further understand MDS and how to treat it. This highly readable resource is the ideal primer on MDS for all members of the multidisciplinary team involved in the care of patients with MDS, including hematologists, hematology trainees, clinical nurse specialists and primary care providers. Table of Contents: • Epidemiology and etiology • Pathogenesis and presentation • Diagnosis and classification • Management • Supporting patients with MDS.

Aunque la incidencia y prevalencia de leucemia está aumentando a nivel mundial, los avances en el diagnóstico y el tratamiento indican que las tasas de supervivencia también están aumentando. Comenzando con una descripción detallada de la hematopoyesis y lo que está mal en caso de la leucemia, esta guía concisa abarca todos los aspectos de los cuatro subtipos más frecuentes de la enfermedad: leucemia mieloide aguda (AML), leucemia linfoblástica aguda (ALL), leucemia mieloide crónica (CML) y leucemia linfocítica crónica (CLL). Este libro considera las causas y factores de riesgo para cada subtipo de leucemia, las pruebas diagnósticas iniciales y confirmatorias (incluyendo métodos de citogenética y genética molecular) y las opciones de tratamiento más recientes. Tanto los efectos de la enfermedad como los efectos adversos del tratamiento siguen representando un desafío complejo y se considera el abordaje multidisciplinario necesario para una atención de apoyo efectiva. Por último, se examinan las complicaciones urgentes que requieren atención de emergencia. Diseñado como una guía integral para enfermeras especializadas, médicos de atención primaria y residentes de hematología/oncología, este recurso ayudará a quienes no son especialistas a identificar la leucemia en etapas tempranas y proporciona una comprensión detallada de la patología y la base genética de la enfermedad, las opciones de tratamiento y los abordajes efectivos a la atención de urgencia y cuidados de apoyo.